Letrozole
Product Images NDC 54868-6252

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Letrozole (NDC 54868-6252). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Image Of 2.5 mg Package Label (6252)

Image Of 2.5 mg Package Label (6252)
LETROZOLE 2.5MG tablet bottle label by Physicians Total Care, Inc., containing 30 tablets. The label includes the NDC number 54868-6252-0, lot number 0000, an expiration date of 01/60, and notes manufacturing by Mylan Pharmaceuticals in Morgantown, WV. A barcode is also visible.*
FDA Label Image

Image Of Chemical Structure (Chemical Structure)

Image Of Chemical Structure (Chemical Structure)
Chemical structure of Letrozole, showing its molecular framework with nitrogen, carbon, and cyano groups as represented by rings and bonds in the diagram.*
FDA Label Image

Image Of Figure 1 (Figure 1)

Image Of Figure 1 (Figure 1)
A Kaplan-Meier survival curve graph depicting Disease-Free Survival (DFS) over 72 months comparing Letrozole and Tamoxifen treatments. The graph includes patient numbers at risk, event counts, and censored data for each treatment group, with solid and dashed lines representing Letrozole and Tamoxifen survival probabilities, respectively. Additional text defines DFS events included in the analysis.*
FDA Label Image

Image Of Figure 2 (Figure 2)

Image Of Figure 2 (Figure 2)
A line chart comparing progression-free survival over months between Letrozole 2.5 mg and Tamoxifen 20 mg. The y-axis represents progression-free proportion, and the x-axis shows time in months, illustrating survival trends for both treatments.*
FDA Label Image

Image Of Figure 3 (Figure 3)

Image Of Figure 3 (Figure 3)
A line graph comparing survival over months between two groups, one starting with letrozole and the other with tamoxifen. The y-axis on the left represents the proportion alive, and the x-axis shows the time in months, illustrating survival trends over approximately 54 months.*
FDA Label Image

Image Of Figure 4 (Figure 4)

Image Of Figure 4 (Figure 4)
A Kaplan-Meier survival curve chart showing time to progression in days for treatment groups including Letrozole 0.5 mg, Letrozole 2.5 mg, and MA. The y-axis represents the proportion of patients without progression, and the x-axis represents time in days, tracking disease progression over nearly 1000 days.*
FDA Label Image

Image Of Figure 5 (Figure 5)

Image Of Figure 5 (Figure 5)
A Kaplan-Meier survival curve chart depicting time to progression in days for three treatment groups: Letrozole 2.5 mg, Letrozole 0.5 mg, and a control group labeled AG. The y-axis represents the proportion without progression, ranging from 0 to 1, while the x-axis shows time in days up to 900.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.